Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

• Main Authors: Suvimol Niyomnaitham, Zheng Quan Toh, Patimaporn Wongprompitak, Laddawan Jansarikit, Kanjana Srisutthisamphan, Sompong Sapsutthipas, Yuparat Jantraphakorn, Natthakarn Mingngamsup, Paul V. Licciardi, Kulkanya Chokephaibulkit
• Other Authors: Siriraj Hospital
• Format: Article
• Published: 2022
• Subjects: Immunology and Microbiology; Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/74178
• Institution: Mahidol University

We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 re...